Thomas, M <br/><br/>
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  10 2018 
 - 2076-2084 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdy326  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carboplatin--administration & dosage<br/>Cisplatin--administration & dosage<br/>Cohort Studies<br/>Etoposide--administration & dosage<br/>Follow-Up Studies<br/>Humans<br/>Immunosuppressive Agents--therapeutic use<br/>Immunotherapy<br/>International Agencies<br/>Leflunomide--therapeutic use<br/>Lung Neoplasms--drug therapy<br/>Maintenance Chemotherapy<br/>Prognosis<br/>Small Cell Lung Carcinoma--drug therapy<br/>Survival Rate<br/>Toll-Like Receptor 9--agonists